Knightsbridge Asset Management, LLC Neu Base Therapeutics, Inc. Transaction History

Knightsbridge Asset Management, LLC

  • $342 Million
  • Q2 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022
SELL
$0.41 - $1.3 $875 - $2,776
-2,136 Reduced 9.56%
20,212 $8,000
Q2 2022

Aug 12, 2022
BUY
$0.82 - $1.93 $9,696 - $22,822
11,825 Added 112.37%
22,348 $23,000
Q1 2022

May 13, 2022
BUY
$1.26 - $2.95 $13,258 - $31,042
10,523 New
10,523 $20,000

About NeuBase Therapeutics, Inc.

NBSE Quotes by TradingView
  • Ticker NBSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 32,258,700
  • Description
  • NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as ...
More about NBSE
Track This Portfolio

Track Knightsbridge Asset Management, LLC Portfolio

Follow Knightsbridge Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Knightsbridge Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Knightsbridge Asset Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email